TSHA
Income statement / Annual
Last year (2024), Taysha Gene Therapies, Inc.'s total revenue was $8.33 M,
a decrease of 46.07% from the previous year.
In 2024, Taysha Gene Therapies, Inc.'s net income was -$89.30 M.
See Taysha Gene Therapies, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$8.33 M |
$15.45 M |
$2.50 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$2.49 M
|
$0.00
|
$9.00 K
|
$0.00
|
| Gross Profit |
$8.33 M
|
$15.45 M
|
$15.00 K
|
$0.00
|
-$9.00 K
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
0.01
|
0
|
0
|
0
|
| Research and Development Expenses |
$66.00 M
|
$56.78 M
|
$91.17 M
|
$131.94 M
|
$31.89 M
|
$987.00 K
|
| General & Administrative Expenses |
$28.95 M
|
$30.05 M
|
$0.00
|
$41.32 M
|
$11.10 M
|
$512.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$384.00 K
|
| Selling, General & Administrative Expenses |
$28.95 M
|
$30.05 M
|
$34.87 M
|
$41.32 M
|
$11.10 M
|
$128.00 K
|
| Other Expenses |
$4.84 M
|
$1.07 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$99.79 M
|
$87.89 M
|
$126.04 M
|
$173.27 M
|
$42.99 M
|
$1.12 M
|
| Cost And Expenses |
$99.79 M
|
$87.89 M
|
$128.53 M
|
$173.27 M
|
$43.00 M
|
$1.12 M
|
| Interest Income |
$6.94 M
|
$3.57 M
|
$249.00 K
|
$172.00 K
|
$49.00 K
|
$0.00
|
| Interest Expense |
$102.00 K
|
$5.00 M
|
$3.80 M
|
$1.43 M
|
$28.00 K
|
$0.00
|
| Depreciation & Amortization |
$1.25 M
|
$1.37 M
|
$2.49 M
|
$492.00 K
|
$9.00 K
|
$4.46 M
|
| EBITDA |
-$87.95 M |
-$105.20 M |
-$159.73 M |
-$172.60 M |
-$59.97 M |
$0.00 |
| EBITDA Ratio |
-10.55
|
-6.81
|
-63.84
|
0
|
0
|
0
|
| Operating Income Ratio |
-10.98
|
-4.69
|
-50.37
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.16 M
|
-$39.13 M
|
-$39.99 M
|
-$1.26 M
|
-$17.01 M
|
$0.00
|
| Income Before Tax |
-$89.30 M
|
-$111.57 M
|
-$166.01 M
|
-$174.52 M
|
-$60.01 M
|
-$1.12 M
|
| Income Before Tax Ratio |
-10.72
|
-7.22
|
-66.35
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$89.30 M
|
-$111.57 M
|
-$166.01 M
|
-$174.52 M
|
-$43.00 M
|
-$1.12 M
|
| Net Income Ratio |
-10.72
|
-7.22
|
-66.35
|
0
|
0
|
0
|
| EPS |
-0.357 |
-0.9608 |
-3.7772 |
-4.6353 |
-3.397 |
-0.0301 |
| EPS Diluted |
-0.357 |
-0.9608 |
-3.7772 |
-4.6353 |
-3.397 |
-0.0301 |
| Weighted Average Shares Out |
$250.13 M
|
$116.12 M
|
$43.95 M
|
$37.65 M
|
$17.67 M
|
$36.99 M
|
| Weighted Average Shares Out Diluted |
$250.13 M
|
$116.12 M
|
$43.95 M
|
$37.65 M
|
$17.67 M
|
$36.99 M
|
| Link |
|
|
|
|
|
|
